NCT04149080

Brief Summary

Statins (HMG-CoA) are widely used in treating patients with hypercholesterolemia. They have also been studied because of their anabolic effects on bone tissue. Statins increase the expression of Bone Morphogenetic Proteins-2 (BMP-2) and Vascular Endothelial Growth Factor (VEGF), which are of important scientific interest in bone regeneration therapy. However, they are expensive and have a short half-life. Therefore, a molecule promoting the endogenous production of BMP-2 and VEGF would be valuable for the field of bone tissue engineering. This study aims to evaluate dimensional changes, level of soft tissue healing, pain/discomfort, and newly formed tissues in post-extraction sockets filling with Simvastatin (SIM) gel covered with polypropylene membranes. Thirty post-extraction sockets of posterior teeth will be randomized allocated in two groups: 1) extractions and socket filling with 1.2% SIM gel and membrane and 2) extraction and socket filling with placebo gel and membrane. The evaluation will be done through clinical analyzes, histomorphometry and micro-computed tomographic images, considering the dimensional changes, the quantity and the quality of tissue formation after extractions. Measurements will be taken before extraction (T1) and 90 days after the extraction (T2). In addition, the perception of pain will be analyzed. The hypothesis is that SIM associated with polypropylene membrane can enhance bone formation in post-extraction sockets compared with the control group.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2017

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

October 30, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 4, 2019

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

November 4, 2019

Status Verified

October 1, 2019

Enrollment Period

2.3 years

First QC Date

October 30, 2019

Last Update Submit

October 30, 2019

Conditions

Keywords

SimvastatinTooth extractionAlveolar socket preservationBone regeneration

Outcome Measures

Primary Outcomes (1)

  • Dimensional change of the alveolar crest

    Including soft and hard tissue, after clinical, histological and tomographic analysis

    90 days

Secondary Outcomes (2)

  • Soft tissue healing

    1 week

  • Pain/discomfort

    1 week

Study Arms (2)

SIM Group

EXPERIMENTAL

Alveolar socket post-extraction filled with Simvastatin covered with polypropylene membrane

Procedure: SIM + polypropylene membrane

Control Group

PLACEBO COMPARATOR

Alveolar socket post-extraction covered with polypropylene membrane

Procedure: Placebo

Interventions

After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.

SIM Group
PlaceboPROCEDURE

After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.

Control Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged over 18 years
  • Healthy patients with indication for dental extraction
  • Teeth adjacent to the extraction site
  • Patients willing to cooperate with the study and who have signed the informed consent form.

You may not qualify if:

  • Patients showing periapical or periodontal infection
  • Patients with severe systemic diseases
  • Patients on medications such as chemotherapy, anticoagulants, corticosteroids, biphosphonates and immunosuppressant drugs,
  • Patients who have chronic diseases decompensated (e.g. hypertension, diabetes, rheumatic diseases, renal, and hepatic)
  • Patients with bone diseases, metabolic (osteomalacia, hypocalcemia and hypercalcemia).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dental Clinical Research Center of the Fluminense Federal University

Niterói, Rio de Janeiro, 24020-140, Brazil

RECRUITING

Related Publications (4)

  • Landry R, Turnbull R, Howley T. Effectiveness of benzydamine HCL in the treatment of periodontal post-surgical patients. Res Clin Forums 10:105-118, 1998

    BACKGROUND
  • Moraschini V, Almeida DCF, Calasans-Maia JA, Diuana Calasans-Maia M. The ability of topical and systemic statins to increase osteogenesis around dental implants: a systematic review of histomorphometric outcomes in animal studies. Int J Oral Maxillofac Surg. 2018 Aug;47(8):1070-1078. doi: 10.1016/j.ijom.2017.12.009. Epub 2018 Jan 17.

  • Barone A, Ricci M, Tonelli P, Santini S, Covani U. Tissue changes of extraction sockets in humans: a comparison of spontaneous healing vs. ridge preservation with secondary soft tissue healing. Clin Oral Implants Res. 2013 Nov;24(11):1231-7. doi: 10.1111/j.1600-0501.2012.02535.x. Epub 2012 Jul 12.

  • Calasans-Maia M, Resende R, Fernandes G, Calasans-Maia J, Alves AT, Granjeiro JM. A randomized controlled clinical trial to evaluate a new xenograft for alveolar socket preservation. Clin Oral Implants Res. 2014 Oct;25(10):1125-30. doi: 10.1111/clr.12237. Epub 2013 Aug 13.

Study Officials

  • Rebecca Cruz, MSc

    Fluminense Federal University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rebecca Cruz, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: 30 subjects will be divided randomly in two groups. The study is triple masked.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MSc.

Study Record Dates

First Submitted

October 30, 2019

First Posted

November 4, 2019

Study Start

November 1, 2017

Primary Completion

March 1, 2020

Study Completion

March 1, 2020

Last Updated

November 4, 2019

Record last verified: 2019-10

Locations